Drugs & Targets FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma December 06, 2024Vol.50 No.45
Drugs & Targets Merus and Partner Therapeutics announce license agreement for the U.S. commercialization of zenocutuzumab in NRG1 fusion-positive cancer December 06, 2024Vol.50 No.45
Drugs & Targets ConcertAI and NeoGenomics announce AI software-as-a-service solution for hematology clinical research December 06, 2024Vol.50 No.45
Capitol Hill As Trump’s second term nears, Republican support for NIH is at a low pointBy stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research November 22, 2024Vol.50 No.44By Paul Goldberg
Patient navigation benefits health systems, improves careInitial data presented at the White House come a year after CMS payment began November 22, 2024Vol.50 No.44By Jacquelyn Cobb
Health Equity Cedars-Sinai spearheads first national certification program for COE staff at cancer centers November 22, 2024Vol.50 No.44By McKenzie Prillaman
Trials & Tribulations Menin inhibitors emerge as new treatment for advanced AML November 22, 2024Vol.50 No.44By Ghayas Issa
In Brief Krish Patel joins Sarah Cannon as director of lymphoma research November 22, 2024Vol.50 No.44
